{'fraction_non_alphanumeric': 0.027419354838709678, 'fraction_numerical': 0.02903225806451613, 'mean_word_length': 4.262711864406779, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
Response to ‘Lack of efficacy of dupilumab in the treatment of keloid disorder’ by MH Tirgan and J Uitto

We have read with interest the letter by Tirgan et al. on a group of 17 patients with keloids referred for treatment with dupilumab,1 according to authors with minimal or no response. However, only 8 patients were actually treated with dupilumab for 2-12 months; 3 for 2-3mo, one for 6mo and 4 for 10-12mo. The patient that per authors had a possible response was treated for 12 months. The responses were either evaluated by the patients or by the author (MT), with no reporting of how the response was evaluated.